JP2012525415A5 - - Google Patents

Download PDF

Info

Publication number
JP2012525415A5
JP2012525415A5 JP2012508655A JP2012508655A JP2012525415A5 JP 2012525415 A5 JP2012525415 A5 JP 2012525415A5 JP 2012508655 A JP2012508655 A JP 2012508655A JP 2012508655 A JP2012508655 A JP 2012508655A JP 2012525415 A5 JP2012525415 A5 JP 2012525415A5
Authority
JP
Japan
Prior art keywords
antagonist
vegf
pdgf
administered
vegf antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012508655A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012525415A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/032816 external-priority patent/WO2010127029A1/en
Publication of JP2012525415A publication Critical patent/JP2012525415A/ja
Publication of JP2012525415A5 publication Critical patent/JP2012525415A5/ja
Pending legal-status Critical Current

Links

JP2012508655A 2009-05-01 2010-04-28 眼科疾患を処置または予防するための方法 Pending JP2012525415A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US17474609P 2009-05-01 2009-05-01
US61/174,746 2009-05-01
US17801009P 2009-05-13 2009-05-13
US61/178,010 2009-05-13
US24578409P 2009-09-25 2009-09-25
US61/245,784 2009-09-25
PCT/US2010/032816 WO2010127029A1 (en) 2009-05-01 2010-04-28 Methods for treating or preventing ophthalmological diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015115569A Division JP2015199749A (ja) 2009-05-01 2015-06-08 眼科疾患を処置または予防するための方法

Publications (2)

Publication Number Publication Date
JP2012525415A JP2012525415A (ja) 2012-10-22
JP2012525415A5 true JP2012525415A5 (enExample) 2013-06-20

Family

ID=43032543

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2012508655A Pending JP2012525415A (ja) 2009-05-01 2010-04-28 眼科疾患を処置または予防するための方法
JP2015115569A Pending JP2015199749A (ja) 2009-05-01 2015-06-08 眼科疾患を処置または予防するための方法
JP2016246245A Pending JP2017081955A (ja) 2009-05-01 2016-12-20 眼科疾患を処置または予防するための方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2015115569A Pending JP2015199749A (ja) 2009-05-01 2015-06-08 眼科疾患を処置または予防するための方法
JP2016246245A Pending JP2017081955A (ja) 2009-05-01 2016-12-20 眼科疾患を処置または予防するための方法

Country Status (7)

Country Link
US (3) US20120100136A1 (enExample)
EP (3) EP3165606A1 (enExample)
JP (3) JP2012525415A (enExample)
AR (1) AR076523A1 (enExample)
CA (1) CA2760687A1 (enExample)
TW (2) TWI528963B (enExample)
WO (1) WO2010127029A1 (enExample)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ592039A (en) 2003-08-27 2013-03-28 Ophthotech Corp Combination therapy for the treatment of ocular neovascular disorders
RS58392B1 (sr) 2008-04-18 2019-04-30 Reata Pharmaceuticals Inc Antioksidantni modulatori inflamacije: derivati oleanoličke kiseline sa amino i drugim modifikacijama na c-17
WO2011075185A1 (en) 2009-12-18 2011-06-23 Oligasis Targeted drug phosphorylcholine polymer conjugates
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
AU2012249658A1 (en) * 2011-04-26 2013-05-09 Regado Biosciences, Inc. A method for manufacturing pegylated oligonucleotides
EA201400064A1 (ru) 2011-06-28 2014-05-30 Байер Хелфкеэ Ллк Офтальмологическая фармацевтическая композиция для местного применения, которая содержит регорафениб
CA2840491A1 (en) 2011-06-28 2013-01-03 Bayer Healthcare Llc Topical ophthalmological pharmaceutical composition containing sorafenib
US20130142796A1 (en) * 2011-12-05 2013-06-06 Subhransu Ray Treatment for angiogenic disorders
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
TWI588560B (zh) 2012-04-05 2017-06-21 布萊恩荷登視覺協會 用於屈光不正之鏡片、裝置、方法及系統
EP2841445B1 (en) 2012-04-27 2017-06-14 Reata Pharmaceuticals, Inc. 2.2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof
JP2015519373A (ja) * 2012-06-01 2015-07-09 オプソテック コーポレイションOphthotech Corporation 抗pdgfアプタマーおよびvegf拮抗薬を含む組成物
US9156897B2 (en) * 2012-06-08 2015-10-13 Alkermes, Inc. Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide
JP2015520230A (ja) * 2012-06-25 2015-07-16 バイエル・ヘルスケア・エルエルシーBayer HealthCareLLC アキシチニブを含んでいる眼科用局所医薬組成物
CN104582685A (zh) 2012-06-25 2015-04-29 拜尔健康护理有限责任公司 含有舒尼替尼的局部眼科药物组合物
AU2013100070B4 (en) * 2012-07-03 2013-04-04 Novartis Ag Use of device
DE202013000688U1 (de) * 2012-07-03 2013-03-05 Novartis Ag Glas-Spritze
US9201250B2 (en) 2012-10-17 2015-12-01 Brien Holden Vision Institute Lenses, devices, methods and systems for refractive error
CA2887655C (en) 2012-10-17 2021-11-02 Brien Holden Vision Institute Lenses, devices, methods and systems for refractive error
US9681805B2 (en) * 2012-11-05 2017-06-20 Babak Kamkar Afferent pupil tester
UY35183A (es) 2012-12-21 2014-07-31 Bayer Healthcare Llc Composición farmacéutica oftalmológica tópica que contiene regorafenib
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
MY170528A (en) 2013-02-18 2019-08-09 Vegenics Pty Ltd Vegfr-3 ligand binding molecules and uses thereof
EP2971033B8 (en) 2013-03-15 2019-07-10 ModernaTX, Inc. Manufacturing methods for production of rna transcripts
EP4279610A3 (en) 2013-03-15 2024-01-03 ModernaTX, Inc. Ribonucleic acid purification
US10077439B2 (en) 2013-03-15 2018-09-18 Modernatx, Inc. Removal of DNA fragments in mRNA production process
WO2014144767A1 (en) 2013-03-15 2014-09-18 Moderna Therapeutics, Inc. Ion exchange purification of mrna
TWI649330B (zh) 2013-04-24 2019-02-01 艾伯維有限公司 甲基巴多索龍之2,2-二氟丙醯胺衍生物、其多晶形及其使用方法
WO2014182635A1 (en) 2013-05-08 2014-11-13 Baldwin Megan E Biomarkers for age-related macular degeneration (amd)
JP2016522249A (ja) * 2013-06-20 2016-07-28 ノバルティス アーゲー 脈絡膜血管新生の治療におけるvegfアンタゴニストの使用
US20160129080A1 (en) * 2013-06-20 2016-05-12 Aaron Osborne Treatment of polypoidal chroidal vasculopathy
BR112016000177A2 (pt) * 2013-07-11 2017-12-12 Novartis Ag usos de um antagonista do vegf no tratamento de doenças neovasculares coriorretinianas e de permeabilidade em pacientes pediátricos, seringa pré-cheia, kit e formulação de liberação lenta
JP2016523956A (ja) * 2013-07-11 2016-08-12 ノバルティス アーゲー 未熟児網膜症の治療におけるvegfアンタゴニストの使用
PL3019619T3 (pl) 2013-07-11 2022-01-10 Modernatx, Inc. Kompozycje zawierające syntetyczne polinkleotydy kodujące białka powiązane z crispr i syntetyczne sgrna oraz sposoby ich stosowania
SI4374873T1 (sl) 2013-07-12 2026-01-30 Astellas Us Llc Sredstvo za uporabo pri zdravljenju ali preprečevanju oftalmoloških stanj
ES2819217T3 (es) 2013-09-08 2021-04-15 Kodiak Sciences Inc Conjugados de polímeros iónicos dipolares y factor VIII
US20170250927A1 (en) * 2013-12-23 2017-08-31 Dali Systems Co. Ltd. Virtual radio access network using software-defined network of remotes and digital multiplexing switches
US10286086B2 (en) 2014-06-19 2019-05-14 Modernatx, Inc. Alternative nucleic acid molecules and uses thereof
WO2015196130A2 (en) * 2014-06-19 2015-12-23 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
WO2015200905A2 (en) 2014-06-28 2015-12-30 Oligasis, Llc Dual pdgf/vegf antagonists
AU2015289656A1 (en) 2014-07-16 2017-02-16 Modernatx, Inc. Circular polynucleotides
WO2016022536A2 (en) 2014-08-04 2016-02-11 MiRagen Therapeutics, Inc. Inhibitors of myh7b and uses thereof
KR20170040798A (ko) * 2014-08-08 2017-04-13 포사이트 비젼4, 인크. 수용체 티로신 키나제 억제제의 안정한 가용성 제제 및 그의 제조 방법
WO2016025313A1 (en) * 2014-08-11 2016-02-18 Samir Patel Methods for treating or preventing ophthalmological conditions
EP3207128B1 (en) 2014-10-17 2022-07-27 Kodiak Sciences Inc. Butyrylcholinesterase zwitterionic polymer conjugates
WO2016141480A1 (en) * 2015-03-09 2016-09-15 Mount Sinai Hospital Tools and methods for using cell division loci to control proliferation of cells
CA2995310A1 (en) * 2015-08-25 2017-03-02 Histide Ag Compounds for inducing tissue formation and uses thereof
EP4101930A1 (en) 2015-09-17 2022-12-14 ModernaTX, Inc. Polynucleotides containing a stabilizing tail region
WO2017049286A1 (en) 2015-09-17 2017-03-23 Moderna Therapeutics, Inc. Polynucleotides containing a morpholino linker
WO2017065559A1 (ko) * 2015-10-15 2017-04-20 (주)알테오젠 Igg fc 도메인을 가지는 융합 단백질의 생산방법
KR101936049B1 (ko) 2015-10-15 2019-01-08 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 생산방법
IL290457B2 (en) 2015-12-30 2025-02-01 Kodiak Sciences Inc Antibodies and their conjugates
KR101795650B1 (ko) 2016-05-12 2017-11-09 인제대학교 산학협력단 아플리버셉트-콜라겐 타입 ii 펩타이드의 키메라 단백질을 유효성분으로 함유하는 혈관신생 억제용 조성물
KR101795653B1 (ko) 2016-05-19 2017-11-09 인제대학교 산학협력단 콜라겐 타입 ii 펩타이드-아플리버셉트의 키메라 단백질을 유효성분으로 함유하는 혈관신생 억제용 조성물
US12385034B2 (en) 2016-06-24 2025-08-12 Modernatx, Inc. Methods and apparatus for filtration
AU2017345470B2 (en) 2016-10-19 2023-08-03 Adverum Biotechnologies, Inc. Modified AAV capsids and uses thereof
CN106778685A (zh) * 2017-01-12 2017-05-31 司马大大(北京)智能系统有限公司 心电图图像识别方法、装置及服务终端
CN109428697B (zh) 2017-08-25 2021-12-28 华为技术有限公司 数据传输方法、网络设备及终端设备
CN108256457B (zh) * 2018-01-09 2021-06-04 东北大学 一种基于深度神经网络的心冲击信号深瓶颈特征提取方法
CA3092588A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
CN108920529A (zh) * 2018-06-07 2018-11-30 北京金山安全软件有限公司 一种数据提取方法、装置及电子设备
JP2022535717A (ja) 2019-05-24 2022-08-10 エンピリコ インク. アンジオポエチン様7(angptl7)関連疾患の処置
PE20240329A1 (es) 2019-06-05 2024-02-27 Regeneron Pharma Dispositivos y metodos para administracion de dosis de precision
CN110257383B (zh) * 2019-06-24 2023-05-26 湖北师范大学 特异性识别邻苯二甲酸二(2-乙基)己酯的核酸适配体及其筛选方法与应用
CN110522902B (zh) * 2019-09-25 2022-10-11 南京农业大学 一种用于建立慢性肾病模型的组合物及其应用
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
KR20260083444A (ko) 2019-11-25 2026-06-05 알케르메스,인코포레이티드 치환된 마크로사이클릭 화합물 및 관련 치료 방법
JP7674383B2 (ja) 2020-03-30 2025-05-09 エフ. ホフマン-ラ ロシュ アーゲー Vegf及びpdgf-bに結合する抗体及び使用方法
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
KR102338093B1 (ko) * 2021-01-14 2021-12-10 국민대학교 산학협력단 (7S)-(+)-시클로펜틸 카바믹산, 8,8-디메틸-2-옥소-6,7-디히드로-2H,8H-피라노[3,2-g]크로멘-7-일-에스테르를 유효성분으로 포함하는 안질환의 예방, 개선 또는 치료용 조성물
CN112675158A (zh) * 2021-01-26 2021-04-20 苏州市立医院 紫草醌在制备脉络膜新生血管治疗药物中的作用
WO2022204267A1 (en) 2021-03-24 2022-09-29 Alkermes, Inc. Upar antibodies and fusion proteins with the same
CN112852749A (zh) * 2021-03-27 2021-05-28 哈尔滨元亨生物药业有限公司 高效分泌犬细小病毒单克隆抗体杂交瘤细胞株c68及利用生物反应器对其进行生产的方法
EP4349852A4 (en) 2021-05-28 2025-09-03 Shanghai Regenelead Therapies Co Ltd RECOMBINANT ADENO-ASSOCIATED VIRUS HAVING A VARIANT CAPSID, AND ITS APPLICATION
CN113466782B (zh) * 2021-06-08 2022-09-13 同济大学 一种基于深度学习(dl)的互耦校正doa估计方法
US12649031B2 (en) 2021-09-08 2026-06-09 Regeneron Pharmaceuticals, Inc. Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation
US20250197859A1 (en) * 2022-03-28 2025-06-19 Empirico Inc. Compositions and methods for the treatment of angiopoietin like 7 (angptl7) related diseases
EP4499834A2 (en) * 2022-03-28 2025-02-05 Empirico Inc. Modified oligonucleotides
WO2023239415A1 (en) * 2022-06-08 2023-12-14 Angrow Company Limited Compositions including cannabinoid and use thereof in the manufacture of a medicament for the treatment of inflammation in a subject
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
CN118766879B (zh) * 2024-07-12 2025-10-10 华中科技大学 蒽醌类化合物aloesaponarin II在制备CVB3病毒抑制剂中的应用
CN118898773B (zh) * 2024-10-09 2024-12-17 江西师范大学 基于多尺度特征融合的医学图像分割方法和设备
CN121177569B (zh) * 2025-11-21 2026-02-24 重庆医科大学附属口腔医院(重庆市口腔医院) 一种感染性骨缺损仿生修复水凝胶支架及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6229002B1 (en) * 1995-06-07 2001-05-08 Nexstar Pharmaceuticlas, Inc. Platelet derived growth factor (PDGF) nucleic acid ligand complexes
US7306799B2 (en) * 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
US7087411B2 (en) * 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
WO2006050498A2 (en) * 2004-11-02 2006-05-11 Archemix Corp. Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US20040253243A1 (en) * 2003-01-21 2004-12-16 David Epstein Aptamer therapeutics useful in ocular pharmacotherapy
US10100316B2 (en) * 2002-11-21 2018-10-16 Archemix Llc Aptamers comprising CPG motifs
NZ592039A (en) * 2003-08-27 2013-03-28 Ophthotech Corp Combination therapy for the treatment of ocular neovascular disorders
CN1980947B (zh) * 2004-04-22 2013-01-30 雷加多生物科学公司 改良的凝血因子调节物
EP1853298A2 (en) * 2005-02-11 2007-11-14 Regeneron Pharmaceuticals, Inc. Therapeutic combination of a vegf antagonist (vegf trap) and an anti-hypertensive agent
JP2009540011A (ja) * 2006-06-12 2009-11-19 エクセジェニックス、インク.ディー/ビー/エー オプコ ヘルス、インク. 血管新生のsiRNA阻害のための組成物及び方法
WO2008153997A1 (en) * 2007-06-07 2008-12-18 Brookwood Pharmaceuticals, Inc. Reduced-mass, long-acting dosage forms

Similar Documents

Publication Publication Date Title
JP2015528454A5 (enExample)
Giddabasappa et al. Axitinib inhibits retinal and choroidal neovascularization in in vitro and in vivo models
JP2014532072A5 (enExample)
CA2947067C (en) Compounds for treating ophthalmic diseases and disorders
Schopf et al. Topical ocular drug delivery to the back of the eye by mucus-penetrating particles
JP5739908B2 (ja) 血管形成関連の眼疾患の処置のための組成物および方法
RU2015117536A (ru) Vegf-нейтрализирующие пролекарства для лечения офтальмологических заболеваний
JP2022183183A5 (enExample)
JP2007503451A5 (enExample)
RU2018128980A (ru) Офтальмологические составы для доставки лекарственных средств к заднему сегменту глаза
JP2019510078A5 (enExample)
JP2010536797A5 (enExample)
JP2016528202A5 (enExample)
AR076796A1 (es) Proteinas de union al antigeno. composicion farmaceutica. uso. procedimiento.
JP2010526780A5 (enExample)
JP2013515739A5 (enExample)
JP2009513668A5 (enExample)
AR076523A1 (es) Metodos para tratar o prevenir enfermedades oftalmologicas. composicion.compuesto
WO2012047966A8 (en) Compositions and methods for treating ocular edema, neovascularization and related diseases
JP2017535285A5 (enExample)
JP2013520405A5 (enExample)
WO2014031429A3 (en) Liposome formulations
JP2014513722A5 (enExample)
JP2013528563A5 (enExample)
KR20140008303A (ko) 안구 혈관 질환의 치료를 위한 투여 요법